Alerts will be sent to your verified email
Verify EmailSTAR
|
Strides Pharma Scien
|
Procter&Gamble Healt
|
Sanofi India
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
230.0 . | n/a | n/a |
|
Number of ANDA's Approved By USFDA
|
215.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
1.84 % | n/a | 0.0 |
|
Financials
|
|||
|
5 yr Average ROE
|
30.1 % | 36.03 % | 50.34 % |
|
5yr average Equity Multiplier
|
2.62 | 1.79 | 5.32 |
|
5yr Average Asset Turnover Ratio
|
0.6 | 0.77 | 0.42 |
|
5yr Avg Net Profit Margin
|
12.9 % | 19.19 % | 22.84 % |
|
Price to Book
|
3.12 | 21.68 | 10.49 |
|
P/E
|
17.42 | 34.78 | 25.37 |
|
5yr Avg Cash Conversion Cycle
|
-51.45 Days | -155.74 Days | -15.2 Days |
|
Inventory Days
|
69.05 Days | 36.01 Days | 67.68 Days |
|
Days Receivable
|
60.35 Days | 40.92 Days | 35.69 Days |
|
Days Payable
|
225.58 Days | 215.28 Days | 75.12 Days |
|
5yr Average Interest Coverage Ratio
|
0.72 | 500.05 | 777.41 |
|
5yr Avg ROCE
|
10.5 % | 30.21 % | 23.73 % |
|
5yr Avg Operating Profit Margin
|
12.17 % | 27.53 % | 25.16 % |
|
5 yr average Debt to Equity
|
1.01 | 0.0 | 0.0 |
|
5yr CAGR Net Profit
|
68.01 % | 4.02 % | 25.59 % |
|
5yr Average Return on Assets
|
10.97 % | 15.5 % | 9.68 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
27.91 % | 51.82 % | 60.4 % |
|
Share Pledged by Promoters
|
27.27 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-0.36 % | 0.0 | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
-2.58 % | 0.95 % | -0.27 % |
|
Strides Pharma Scien
|
Procter&Gamble Healt
|
Sanofi India
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
-
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
|
Customer Segment
|
Customer Segment
|
-
|
-
|
|
Asset Break-Up - Segment Wise
|
Asset Break-Up - Segment Wise
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|